探索有利风险前列腺癌男性接受推荐主动监测的差异
本研究结合密歇根泌尿外科质量改进协作组的前瞻性注册数据与2014至2018年保险索赔数据,评估有利风险前列腺癌主动监测男性接受推荐监测的情况。在随访≥36个月的246例男性中,仅56.5%接受了全部推荐监测,19%的接受差异归因于泌尿科医生个体,年龄≥75岁者接受磁共振成像/活检的调整比值比为0.07(95%CI 0.01-0.81)。
要点
- 随访≥36个月的246例男性中,56.5%接受了全部推荐监测。
- 69.9%接受年度前列腺特异性抗原检测,72.8%接受磁共振成像/活检。
- 19%的接受差异归因于泌尿科医生个体,年龄≥75岁者接受磁共振成像/活检的调整比值比为0.07。
核心结论
- 近半数有利风险前列腺癌主动监测男性未接受全部推荐监测。
- 泌尿科医生对推荐检测的接受有实质性影响,探索如何利用患者及其与初级保健提供者的就诊来积极影响接受似乎是有必要的。
研究设计与样本
- 结合密歇根泌尿外科质量改进协作组(46家学术和社区泌尿外科实践)的前瞻性注册数据与2014至2018年保险索赔数据。
- 在随访≥36个月的246例有利风险前列腺癌主动监测男性中评估推荐监测的接受情况。
- 采用多水平分析检验泌尿科医生、泌尿科医生和初级保健提供者就诊以及患者人口学和临床因素对接受差异的影响。
主要发现
- 3年主动监测期间,56.5%的男性接受了全部推荐监测。
- 69.9%接受年度前列腺特异性抗原检测,72.8%接受磁共振成像/活检。
- 19%的接受差异归因于泌尿科医生个体。
- 提供者就诊增加与接受推荐监测无显著相关。
- 年龄≥75岁 vs <55岁男性接受磁共振成像/活检的调整比值比为0.07(95%CI 0.01-0.81)。
关键数值与推荐
- 推荐监测按协作组低强度标准定义:年度前列腺特异性抗原检测以及每3年一次磁共振成像或前列腺活检。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Men on active surveillance for favorable-risk prostate cancer do not receive all the recommended testing. Reasons for variation in receipt are unknown. MATERIALS AND METHODS: We combined prospective registry data from the Michigan Urological Surgery Improvement Collaborative, a collaborative of 46 academic and community urology practices across Michigan, with insurance claims from 2014 to 2018 for men on active surveillance for favorable-risk prostate cancer. We defined receipt of recommended surveillance according to the collaborative's low-intensity criteria as: annual prostate specific antigen testing and either magnetic resonance imaging or prostate biopsy every 3 years. We assessed receipt of recommended surveillance among men with ≥36 months of followup (246). We conducted multilevel analyses to examine the influence of the urologist, urologist and primary care provider visits, and patient demographic and clinical factors on variation in receipt. RESULTS: During 3 years of active surveillance, just over half of men (56.5%) received all recommended surveillance testing (69.9% annual prostate specific antigen testing, 72.8% magnetic resonance imaging/biopsy). We found 19% of the variation in receipt was attributed to individual urologists. While increasing provider visits were not significantly associated with receipt, older men were less likely to receive magnetic resonance imaging/biopsy (≥75 vs <55 years, adjusted odds ratio 0.07; 95% confidence interval 0.01-0.81). CONCLUSIONS: Nearly half of men on active surveillance for favorable-risk prostate cancer did not receive all recommended surveillance. While urologists substantially influenced receipt of recommended testing, exploring how to leverage patients and their visits with their primary care providers to positively influence receipt appears warranted.
引用
- Radhakrishnan A, Wallner LP, Skolarus TA, et al. Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer. J Urol. 2022. PMID: 35522191. doi:10.1097/JU.0000000000002734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。